Logo image of IPHA

INNATE PHARMA SA-SPONS ADR (IPHA) Stock Fundamental Analysis

NASDAQ:IPHA - Nasdaq - US45781K2042 - ADR - Currency: USD

1.9791  +0.1 (+5.27%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IPHA. IPHA was compared to 556 industry peers in the Biotechnology industry. IPHA may be in some trouble as it scores bad on both profitability and health. IPHA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IPHA had negative earnings in the past year.
IPHA had a negative operating cash flow in the past year.
IPHA had negative earnings in each of the past 5 years.
IPHA had a negative operating cash flow in each of the past 5 years.
IPHA Yearly Net Income VS EBIT VS OCF VS FCFIPHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

1.2 Ratios

With a Return On Assets value of -44.54%, IPHA perfoms like the industry average, outperforming 52.88% of the companies in the same industry.
With a Return On Equity value of -560.01%, IPHA is not doing good in the industry: 78.60% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -44.54%
ROE -560.01%
ROIC N/A
ROA(3y)-25.61%
ROA(5y)-23.47%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
IPHA Yearly ROA, ROE, ROICIPHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

IPHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IPHA Yearly Profit, Operating, Gross MarginsIPHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IPHA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IPHA has been increased compared to 5 years ago.
The debt/assets ratio for IPHA is higher compared to a year ago.
IPHA Yearly Shares OutstandingIPHA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPHA Yearly Total Debt VS Total AssetsIPHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -4.85, we must say that IPHA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.85, IPHA is in line with its industry, outperforming 40.47% of the companies in the same industry.
A Debt/Equity ratio of 8.02 is on the high side and indicates that IPHA has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 8.02, IPHA is doing worse than 83.63% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 8.02
Debt/FCF N/A
Altman-Z -4.85
ROIC/WACCN/A
WACC7.34%
IPHA Yearly LT Debt VS Equity VS FCFIPHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 2.60 indicates that IPHA has no problem at all paying its short term obligations.
IPHA's Current ratio of 2.60 is on the low side compared to the rest of the industry. IPHA is outperformed by 68.70% of its industry peers.
A Quick Ratio of 2.60 indicates that IPHA has no problem at all paying its short term obligations.
IPHA has a Quick ratio of 2.60. This is in the lower half of the industry: IPHA underperforms 66.73% of its industry peers.
Industry RankSector Rank
Current Ratio 2.6
Quick Ratio 2.6
IPHA Yearly Current Assets VS Current LiabilitesIPHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

IPHA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -549.63%.
The Revenue for IPHA has decreased by -75.68% in the past year. This is quite bad
IPHA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -28.80% yearly.
EPS 1Y (TTM)-549.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.49%
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-73.85%

3.2 Future

The Earnings Per Share is expected to decrease by -14.00% on average over the next years. This is quite bad
IPHA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.06% yearly.
EPS Next Y121.73%
EPS Next 2Y75.86%
EPS Next 3Y-14%
EPS Next 5YN/A
Revenue Next Year86.96%
Revenue Next 2Y85.05%
Revenue Next 3Y29.35%
Revenue Next 5Y43.06%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IPHA Yearly Revenue VS EstimatesIPHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
IPHA Yearly EPS VS EstimatesIPHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IPHA. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 21.57, the valuation of IPHA can be described as rather expensive.
IPHA's Price/Forward Earnings ratio is rather cheap when compared to the industry. IPHA is cheaper than 92.63% of the companies in the same industry.
IPHA is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 37.36, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 21.57
IPHA Price Earnings VS Forward Price EarningsIPHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPHA Per share dataIPHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

IPHA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
IPHA's earnings are expected to decrease with -14.00% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y75.86%
EPS Next 3Y-14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IPHA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNATE PHARMA SA-SPONS ADR

NASDAQ:IPHA (7/23/2025, 4:30:02 PM)

1.9791

+0.1 (+5.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)09-17 2025-09-17
Inst Owners10.09%
Inst Owner Change-39.56%
Ins Owners2.18%
Ins Owner ChangeN/A
Market Cap182.39M
Analysts78
Price Target6.65 (236.01%)
Short Float %0.1%
Short Ratio3.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.44%
PT rev (3m)52.42%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-9.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 21.57
P/S 12.35
P/FCF N/A
P/OCF N/A
P/B 17.65
P/tB 17.65
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)0.09
Fwd EY4.64%
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.16
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.54%
ROE -560.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.61%
ROA(5y)-23.47%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 8.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.61%
Cap/Sales 3.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.6
Quick Ratio 2.6
Altman-Z -4.85
F-Score1
WACC7.34%
ROIC/WACCN/A
Cap/Depr(3y)22.77%
Cap/Depr(5y)23.45%
Cap/Sales(3y)3.3%
Cap/Sales(5y)8.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-549.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.49%
EPS Next Y121.73%
EPS Next 2Y75.86%
EPS Next 3Y-14%
EPS Next 5YN/A
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-73.85%
Revenue Next Year86.96%
Revenue Next 2Y85.05%
Revenue Next 3Y29.35%
Revenue Next 5Y43.06%
EBIT growth 1Y-307.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.78%
EBIT Next 3Y30.44%
EBIT Next 5YN/A
FCF growth 1Y79.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.82%
OCF growth 3YN/A
OCF growth 5YN/A